ImaginAb Announces Extension Of Long-Standing Partnership With Boehringer Ingelheim

LOS ANGELES: LOS ANGELES, July 23, 2021 /PRNewswire/ -- ImaginAb Inc, a market leading global biotechnology company, focused on developing next generation immuno oncology imaging agents and therapeutic radiopharmaceuticals (RPT), today announced the signing of a new significant multi-year, non-exclusive license agreement with Boehringer Ingelheim. The agreement, which builds on...

Click to view original post